U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
LEXINGTON, Mass., March 30, 2017 -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists will present data from its IRAK4 kinase inhibitor development candidate, CA-4948, at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 1 – 5, 2017 in Washington, D.C. Curis has exclusive license to CA-4948 under a collaboration agreement with Aurigene established in 2015.
Additional information follows. Abstracts can be accessed at www.aacr.org.
| Poster Presentation | ||
| Date/Time: | Monday, Apr. 3, 2017, 8:00 AM - 12:00 PM | |
| Session Title: | Novel Molecular Targets 1 | |
| Session Category: | Experimental and Molecular Therapeutics | |
| Presentation Title: | Efficacy of the IRAK4 Inhibitor CA-4948 in Patient-Derived Xenograft Models of Diffuse Large B Cell Lymphoma | |
| Abstract Number: | 1168 |
About Curis, Inc.
Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: Company Contact: James E. Dentzer Chief Financial Officer & Chief Administrative Officer 617-503-6500 [email protected] Media Contact: David Schull Russo Partners 212-845-4271 [email protected]
